Group 1 - Double-Helix Pharmaceutical announced that its associate, Changfeng Pharmaceutical, is expected to be listed on the Hong Kong Stock Exchange on October 8, 2025, with a global offering of 41.198 million shares priced at HKD 14.75 each. Double-Helix holds approximately 3.68% of Changfeng's shares, with a lock-up period of 12 months post-listing [1] - Changfeng Pharmaceutical is involved in the pharmaceutical industry, specifically in the research and development of gene-engineered drugs [2] Group 2 - Lio Corporation has submitted an application to the Hong Kong Stock Exchange for issuing H-shares and listing on the main board [3] - Lio Corporation operates in the mechanical manufacturing and digital marketing sectors [3] Group 3 - Changjiang Securities received approval from the China Securities Regulatory Commission to issue corporate bonds totaling no more than CNY 20 billion, valid for 24 months [4] - Changjiang Securities provides services such as securities and futures brokerage, financial product distribution, investment advisory, asset custody, and margin financing [4] Group 4 - Jingye Intelligent plans to acquire 51% of Hefei Shengwen Information Technology for CNY 108 million, focusing on engineering information technology and intelligent products [5][6] - Jingye Intelligent specializes in the research, development, production, and sales of special robots and intelligent equipment systems [6] Group 5 - Aimeike's subsidiary received approval for the registration of Minoxidil topical solution, a non-prescription drug for treating hair loss [7][8] - Aimeike is engaged in the research, development, production, and sales of biomedical materials and biopharmaceuticals [8] Group 6 - Dalian Heavy Industry expects a net profit of CNY 474 million to CNY 508 million for the first three quarters of 2025, representing a year-on-year increase of 19.91% to 28.52% [9] - Dalian Heavy Industry specializes in the design, manufacturing, assembly, and installation of major technical equipment [9] Group 7 - Huayou Cobalt signed supply agreements with LGES for a total of approximately 76,000 tons of ternary precursor products from 2026 to 2030 [10][11] - Huayou Cobalt focuses on the research, manufacturing, and sales of new energy lithium battery materials and cobalt new materials [11] Group 8 - Zhenjiang Co. plans to reduce its shareholding by up to 5.529 million shares, not exceeding 3% of the total share capital, due to personal funding needs [12] - Zhenjiang Co. is involved in the design, processing, and sales of wind power equipment and components [12] Group 9 - Watson Bio's subsidiary received a drug registration certificate for a 13-valent pneumococcal polysaccharide conjugate vaccine for children [14][15] - Watson Bio specializes in the research, development, production, and sales of human vaccines and biopharmaceuticals [15] Group 10 - Yikang Pharmaceutical's major shareholder plans to reduce holdings by up to 42 million shares, not exceeding 2.04% of the total share capital, due to personal funding needs [16] - Yikang Pharmaceutical is engaged in the production and sales of excipients, raw materials, finished drugs, and new energy materials [16] Group 11 - Sichuan Gold's shareholder plans to reduce holdings by up to 7.56 million shares, accounting for 1.80% of the total share capital [19] - Sichuan Gold focuses on the construction, mining, and sales of gold mines [19] Group 12 - Kangchen Pharmaceutical received approval for a clinical trial of an innovative drug for treating advanced esophageal squamous cell carcinoma [20][21] - Kangchen Pharmaceutical specializes in the manufacturing of chemical drug formulations [21] Group 13 - UCloud plans to repurchase shares worth between CNY 8 million and CNY 10 million for employee stock ownership plans [22] - UCloud provides cloud computing services centered on IT infrastructure [22] Group 14 - Woton Technology announced an adjustment to its share repurchase plan, raising the price cap to CNY 60 per share [24] - Woton Technology specializes in the research, manufacturing, and sales of separation membrane products [24] Group 15 - Five Continents Medical announced plans for shareholders to reduce holdings by up to 126,530 shares, accounting for 1.8606% of the total share capital [26] - Five Continents Medical focuses on the research, manufacturing, and sales of disposable sterile infusion medical devices [26] Group 16 - CIMC Group plans to repurchase A-shares with a total amount not exceeding CNY 5 billion [27] - CIMC Group specializes in logistics and energy equipment solutions [27] Group 17 - Zhifei Biological's subsidiary received a drug registration certificate for a trivalent influenza vaccine suitable for individuals aged 3 and above [29][30] - Zhifei Biological is involved in the research, development, production, and sales of vaccines and biological products [30]

Core Viewpoint - Kangchen Pharmaceutical (603590.SH) has received approval from the National Medical Products Administration for clinical trials of its innovative drug KC1036, aimed at treating advanced recurrent or metastatic esophageal squamous cell carcinoma in combination with PD-1 antibodies and platinum-based chemotherapy [1] Group 1: Product Development - KC1036 is a self-developed Class 1 innovative chemical drug with global intellectual property rights held by the company [1] - The drug exerts anti-tumor activity by inhibiting multiple targets such as VEGFR2 and AXL, demonstrating strong vascular targeting of VEGFR and inhibiting tumor cell growth [1] - Inhibiting AXL can enhance the host's anti-tumor immune response, thereby preventing immune evasion by tumors [1] Group 2: Clinical Research - KC1036 is currently undergoing clinical research for multiple indications, including gastrointestinal tumors, thymic tumors, and pediatric rhabdomyosarcoma [1] - Over 300 subjects have been enrolled in the clinical studies for KC1036 to date, with existing results showing outstanding anti-tumor activity, as well as good safety and tolerability [1]

Core Viewpoint - Kangchen Pharmaceutical (603590.SH) has received approval from the National Medical Products Administration for clinical trials of its innovative chemical drug KC1036, aimed at treating advanced recurrent or metastatic esophageal squamous cell carcinoma in combination with PD-1 antibodies and platinum-based chemotherapy [1] Group 1: Product Development - KC1036 is a self-developed innovative chemical drug with global intellectual property rights held by the company [1] - The drug exhibits anti-tumor activity by inhibiting multiple targets such as VEGFR2 and AXL, demonstrating strong vascular targeting and tumor cell growth suppression [1] - Clinical studies for KC1036 are ongoing for various indications, including gastrointestinal tumors, thymic tumors, and pediatric Ewing sarcoma, with over 300 subjects enrolled to date [1] Group 2: Clinical Trial Results - Preliminary clinical research results indicate significant anti-tumor activity, along with good safety and tolerability profiles for KC1036 [1]

Core Viewpoint - Kangchen Pharmaceutical has received approval from the National Medical Products Administration for clinical trials of its innovative chemical drug KC1036, aimed at treating advanced recurrent or metastatic esophageal squamous cell carcinoma in combination with PD-1 antibodies and platinum-based chemotherapy [1] Group 1: Product Development - KC1036 is a self-developed innovative chemical drug classified as a Class 1 new drug [1] - The drug targets multiple pathways by inhibiting VEGFR2 and AXL to achieve anti-tumor activity [1] - KC1036 exhibits strong vascular targeting of VEGFR, inhibiting tumor cell growth, and improving host anti-tumor immune response by suppressing AXL, thus preventing immune evasion by tumors [1] Group 2: Clinical Research - Clinical trials for KC1036 are set to commence shortly, with over 300 subjects already enrolled in ongoing clinical studies for multiple indications [1]